Video: President takes a spin at auto show

At the Washington auto show, President Obama touted the rebound of the US auto industry while his spokesman, Jay Carney batted away questions about America?s use of drones. NBC?s Kristen Welker reports.

Related Links:

http://twitter.com/nbcnightlynews

Top of page

Source: http://video.msnbc.msn.com/nightly-news/46211630/

9 11 conspiracy theories zeitgeist bush ellie goulding ginger aron ralston aron ralston

'X Factor' shakeup: Paula, Steve, Nicole all out?

"X Factor" host Steve Jones, second from left, and judge Nicole Scherzinger won't be back for season two, but word is Simon Cowell's pal Paula Abdul is also out.

By Anna Chan

Talk about after-hours drama!

"X Factor" host Steve Jones announced on Twitter Monday afternoon that he was leaving the singing competition after the show's inaugural season, and shortly after, Fox confirmed that judge Nicole Scherzinger is also gone.

But Jones and Scherzinger reportedly aren't the only two who went to the chopping block. Show insiders told our pals at E! Online that judge Paula Abdul is also not being asked back for season two despite her long history with former "Idol" co-judge and "X Factor" executive producer Simon Cowell.

"She found out today," a show source told E! Online. "At this point, the only ones staying are Simon and (judge)?L.A. Reid."

Fox has not yet confirmed reports of Abdul's rumored departure.

A show insider told TheWrap.com that producers had expected Abdul to be the "goofy" one on the show, but "was so bad that it made none of it work."

According to TheWrap's source, part of the issue stems from where Fox decided to spend money on the show: The majority of it reportedly went to fancy production work and a great set, while Abdul received a $1 million salary. She earned about $3.5 million during her final season as a judge on "Idol," according to reports.

Abdul has not yet released a statement.

On Monday afternoon, Jones tweeted, "I wont be hosting next seasons XFactor which is a shame but I cant [sic] complain as I've had a great time. Good luck to everyone on the show."

That Scherzinger is out is no huge surprise. Shortly after the season ended, she said at an "X Factor" press conference that the job was much tougher than she had anticipated. "The elimination process has been really hard ... it?s something I could have never prepared for," she said at the time. Reports differ on whether she quit or was let go. A source told E! Online that the former Pussycat Doll wants to focus on her music career, while show insiders told TheWrap that she was fired. Regardless, a Fox spokesperson has confirmed her exit.

Another "X Factor" insider also told E! online that "Simon wants to take the show in a different direction."

With at least two, possibly three, of the show's original cast gone, now he has his chance to right his ship. Prior to the launch of the U.S. version of "X Factor," Cowell said that if the show didn't debut with 20 million viewers, it would be a "disappointment." The show drew about 12.5 million viewers on premiere night.

According to TheWrap, the folks behind "X Factor" are already looking for replacements for the judges and host.

Who would be your picks to replace the three? Tell us on our Facebook page!

{"contentId":"10275867","totalVotes":"6223"}

Are you surprised by the exits?

?

Related content:

Source: http://theclicker.today.msnbc.msn.com/_news/2012/01/31/10275867-nicole-scherzinger-out-as-x-factor-judge-paula-abdul-may-be-gone-too

tyler perry tupac tupac shakur nfl power rankings houston news us news and world report college rankings us news and world report college rankings

DNDi and Abbott expand partnership to boost innovation for neglected tropical diseases

Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Violaine Dallenbach
vdallenbach@dndi.org
41-229-069-247
Drugs for Neglected Diseases Initiative

Geneva, Switzerland -- The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.

Since 2009, Abbott has provided compounds for DNDi to screen for activity against neglected diseases. This new agreement expands this relationship, and provides DNDi access to selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.

"Innovative product development partnerships have significant potential for addressing neglected diseases," said

Dr. John Leonard, senior vice president, Pharmaceuticals, Research and Development, Abbott. "By combining the unique scientific expertise and resources of DNDi and Abbott, we look forward to accelerating research to find practical new treatment options for people affected by these diseases."

"Abbott has demonstrated a great level of commitment by partnering with DNDi to share not only its compounds, but also its expertise and resources. For DNDi, this implies a new critical mass of knowledge to pursue our goals of addressing the unmet needs of neglected patients in the poorest areas of the world," said Dr Bernard Pcoul, Executive Director of DNDi.

Equitable access to treatments for neglected diseases in all endemic countries, not only least-developed countries, is at the core of this agreement, and DNDi has committed to ensuring the lowest sustainable pricing for any products developed and distributed as a result of the agreement. Intellectual property (IP) related to this agreement, existing relevant Abbott IP and new IP generated by this collaboration will be subject to a principle of non-exclusive licensing to address neglected diseases in endemic countries. Under the agreement, Abbott has the right of first negotiation to become DNDi's development and distribution partner. DNDi is free to engage other partners if Abbott chooses not to serve as a development and distribution partner.

The agreement, in short implies:

• Both DNDi and Abbott share their unique scientific expertise and resources to advance the development of drugs adapted to patient needs.
• DNDi gains access to Abbott compounds, data and information to accelerate drug development.
• Non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility, thus expanding the potential of drug development.
• Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.

###

For more information please contact:

Violaine Dallenbach
Press and Communication Manager, DNDi
vdallenbach@dndi.org
Tel: 41-22-906-92-47

Colin McBean
Abbott
colin.mcbean@abbott.com
Tel: 847-938-3083

About the London NTD event

The commitments announced by DNDi are a key part of a new, coordinated push by a diverse range of public and private partners to combat 10 Neglected Tropical Diseases (NTDs) by 2020. Today, 13 pharmaceutical companies, the U.S. and U.K. governments, the Bill & Melinda Gates Foundation, the World Bank and officials from NTD-endemic countries pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the billion people worldwide affected by NTDs.

In the largest coordinated effort to date to combat NTDs, the group announced at an event at the Royal College of Physicians that they would: sustain or expand existing drug donation programs to meet demand through 2020; share expertise and compounds to accelerate research and development of new drugs; and provide more than US$785 million to support R&D efforts and strengthen drug distribution and implementation programmes. The partners also signed onto the "London Declaration on Neglected Tropical Diseases," in which they pledged new levels of collaboration and tracking and reporting of progress.

New funding commitments will fully support work toward the eradication of Guinea worm, as well as expedite progress toward the 2020 goals of: elimination for lymphatic filariasis, blinding trachoma, sleeping sickness and leprosy; and control of soil-transmitted helminthes, schistosomiasis, river blindness, Chagas and visceral leishmaniasis.

About Neglected Tropical Diseases

Neglected diseases are a group of tropical infections that disproportionately affect the world's poor and marginalized populations. According to the World Health Organization (WHO), more than a billion people or one-sixth of the global population suffer from one or more tropical infectious diseases. The partnership between DNDi and Abbott is focused on finding new treatments to address the following diseases:

Chagas disease is endemic in 21 countries across Latin America and kills more people in the region than any other parasite-borne disease, including malaria. In total, 100 million people are at risk worldwide and patient numbers are growing in non-endemic countries such as the United States, Australia, and Europe. The disease is transmitted by an insect known as the "kissing bug" and, without treatment, is potentially fatal. Existing treatments have an unsatisfactory cure rate and can have toxic side effects.

Helminth infections include filarial diseases, onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) caused by parasitic worms, which inflict the heaviest socioeconomic burden of all the neglected tropical diseases and affect millions in poverty-stricken areas. Current treatments for these diseases cannot be used for patients who are infected with a related nematode worm, Loa loa, because of the severe side effects caused by rapid killing of juvenile Loa loa worms. There is an urgent need for a new treatment for onchocerciasis and lymphatic filariasis in Loa loa endemic regions.

Leishmaniasis occurs in 98 countries, placing 350 million people at risk worldwide. The parasite that leads to infection is called Leishmania and transmitted by sandflies. Leishmaniasis is a poverty-associated disease with several different forms. Visceral leismaniasis, which is fatal without treatment, and cutaneous leshmaniasis are the most common. Existing treatments are difficult to administer, toxic, and costly. Drug resistance also is an increasing problem.

Sleeping sickness, or Human African Trypanosomiasis (HAT), is endemic in 36 African countries and around 60 million people are at risk of being infected. HAT is transmitted by the tsetse fly and is fatal without treatment. Up until 2009, existing treatments for stage 2 of the disease were toxic or difficult to administer. In 2009, DNDi and its partners launched the first new treatment for HAT in 25 years.

About Drugs for Neglected Diseases initiative (DNDi)

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, paediatric HIV, and malaria. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council for Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The Special Programme for Tropical Disease Research (TDR) serves as a permanent observer. Since its inception, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease. http://www.dndi.org

About Abbott

Abbott and its philanthropic foundation, the Abbott Fund, are supporting innovative new efforts to advance the prevention, diagnosis and treatment of neglected diseases around the world. In 2009, Abbott created an Executive Council for Neglected Diseases to coordinate efforts across the company to contribute innovative technologies, drug compounds and scientific expertise, working in partnership with non-profit organizations, academic research institutions and multilateral agencies. The Abbott Fund also supports programs to advance research and expand community education and outreach on neglected diseases.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's website at http://www.abbott.com.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Violaine Dallenbach
vdallenbach@dndi.org
41-229-069-247
Drugs for Neglected Diseases Initiative

Geneva, Switzerland -- The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.

Since 2009, Abbott has provided compounds for DNDi to screen for activity against neglected diseases. This new agreement expands this relationship, and provides DNDi access to selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.

"Innovative product development partnerships have significant potential for addressing neglected diseases," said

Dr. John Leonard, senior vice president, Pharmaceuticals, Research and Development, Abbott. "By combining the unique scientific expertise and resources of DNDi and Abbott, we look forward to accelerating research to find practical new treatment options for people affected by these diseases."

"Abbott has demonstrated a great level of commitment by partnering with DNDi to share not only its compounds, but also its expertise and resources. For DNDi, this implies a new critical mass of knowledge to pursue our goals of addressing the unmet needs of neglected patients in the poorest areas of the world," said Dr Bernard Pcoul, Executive Director of DNDi.

Equitable access to treatments for neglected diseases in all endemic countries, not only least-developed countries, is at the core of this agreement, and DNDi has committed to ensuring the lowest sustainable pricing for any products developed and distributed as a result of the agreement. Intellectual property (IP) related to this agreement, existing relevant Abbott IP and new IP generated by this collaboration will be subject to a principle of non-exclusive licensing to address neglected diseases in endemic countries. Under the agreement, Abbott has the right of first negotiation to become DNDi's development and distribution partner. DNDi is free to engage other partners if Abbott chooses not to serve as a development and distribution partner.

The agreement, in short implies:

• Both DNDi and Abbott share their unique scientific expertise and resources to advance the development of drugs adapted to patient needs.
• DNDi gains access to Abbott compounds, data and information to accelerate drug development.
• Non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility, thus expanding the potential of drug development.
• Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.

###

For more information please contact:

Violaine Dallenbach
Press and Communication Manager, DNDi
vdallenbach@dndi.org
Tel: 41-22-906-92-47

Colin McBean
Abbott
colin.mcbean@abbott.com
Tel: 847-938-3083

About the London NTD event

The commitments announced by DNDi are a key part of a new, coordinated push by a diverse range of public and private partners to combat 10 Neglected Tropical Diseases (NTDs) by 2020. Today, 13 pharmaceutical companies, the U.S. and U.K. governments, the Bill & Melinda Gates Foundation, the World Bank and officials from NTD-endemic countries pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the billion people worldwide affected by NTDs.

In the largest coordinated effort to date to combat NTDs, the group announced at an event at the Royal College of Physicians that they would: sustain or expand existing drug donation programs to meet demand through 2020; share expertise and compounds to accelerate research and development of new drugs; and provide more than US$785 million to support R&D efforts and strengthen drug distribution and implementation programmes. The partners also signed onto the "London Declaration on Neglected Tropical Diseases," in which they pledged new levels of collaboration and tracking and reporting of progress.

New funding commitments will fully support work toward the eradication of Guinea worm, as well as expedite progress toward the 2020 goals of: elimination for lymphatic filariasis, blinding trachoma, sleeping sickness and leprosy; and control of soil-transmitted helminthes, schistosomiasis, river blindness, Chagas and visceral leishmaniasis.

About Neglected Tropical Diseases

Neglected diseases are a group of tropical infections that disproportionately affect the world's poor and marginalized populations. According to the World Health Organization (WHO), more than a billion people or one-sixth of the global population suffer from one or more tropical infectious diseases. The partnership between DNDi and Abbott is focused on finding new treatments to address the following diseases:

Chagas disease is endemic in 21 countries across Latin America and kills more people in the region than any other parasite-borne disease, including malaria. In total, 100 million people are at risk worldwide and patient numbers are growing in non-endemic countries such as the United States, Australia, and Europe. The disease is transmitted by an insect known as the "kissing bug" and, without treatment, is potentially fatal. Existing treatments have an unsatisfactory cure rate and can have toxic side effects.

Helminth infections include filarial diseases, onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) caused by parasitic worms, which inflict the heaviest socioeconomic burden of all the neglected tropical diseases and affect millions in poverty-stricken areas. Current treatments for these diseases cannot be used for patients who are infected with a related nematode worm, Loa loa, because of the severe side effects caused by rapid killing of juvenile Loa loa worms. There is an urgent need for a new treatment for onchocerciasis and lymphatic filariasis in Loa loa endemic regions.

Leishmaniasis occurs in 98 countries, placing 350 million people at risk worldwide. The parasite that leads to infection is called Leishmania and transmitted by sandflies. Leishmaniasis is a poverty-associated disease with several different forms. Visceral leismaniasis, which is fatal without treatment, and cutaneous leshmaniasis are the most common. Existing treatments are difficult to administer, toxic, and costly. Drug resistance also is an increasing problem.

Sleeping sickness, or Human African Trypanosomiasis (HAT), is endemic in 36 African countries and around 60 million people are at risk of being infected. HAT is transmitted by the tsetse fly and is fatal without treatment. Up until 2009, existing treatments for stage 2 of the disease were toxic or difficult to administer. In 2009, DNDi and its partners launched the first new treatment for HAT in 25 years.

About Drugs for Neglected Diseases initiative (DNDi)

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, paediatric HIV, and malaria. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council for Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The Special Programme for Tropical Disease Research (TDR) serves as a permanent observer. Since its inception, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease. http://www.dndi.org

About Abbott

Abbott and its philanthropic foundation, the Abbott Fund, are supporting innovative new efforts to advance the prevention, diagnosis and treatment of neglected diseases around the world. In 2009, Abbott created an Executive Council for Neglected Diseases to coordinate efforts across the company to contribute innovative technologies, drug compounds and scientific expertise, working in partnership with non-profit organizations, academic research institutions and multilateral agencies. The Abbott Fund also supports programs to advance research and expand community education and outreach on neglected diseases.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's website at http://www.abbott.com.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2012-01/dfnd-daa012712.php

alot alot are you afraid of the dark are you afraid of the dark dallas news google tv cornel west

Madonna Goes Cheerleader Chic In New Video

'Give Me All Your Luvin' ' tease will air on 'American Idol' this Thursday, followed by full-length premiere on Friday.
By Jocelyn Vena

Madonna
Photo: Jon Furniss/ WireImage

Madonna teased her new music video last week with a simple phrase: pom-poms.

Well, the Queen of Pop wasn't lying. In a new blink-and-you'll-miss-it clip from her "Give Me All Your Luvin' " video, Madonna is definitely getting her cheerleader on. The tease appears in an ad for this week's "American Idol," where a preview for the video will make its world debut ahead of the video's proper Friday premiere.

The Mega Force-directed video was shot in December and made headlines when Nicki Minaj tweeted that she and Madge shared a kiss on set.

In a sea of quick-cut images from the fuller "first look," Madonna dons all black (leather jacket, short shorts) while she hangs with rappers Nicki Minaj and M.I.A., who are wearing red and black cheerleader uniforms. Madge is also spotted hanging with football players in the same color uniforms.

The debut of the video fittingly comes two days before Madonna plays in front of real cheerleaders and football players at the Super Bowl game on Sunday, where Nicki, M.I.A., Cee Lo Green and LMFAO are all rumored to be hitting the stage with her when the New England Patriots face off against the New York Giants in Indianapolis.

This is going to be a big week for Madonna fans. On Friday, not only does the video for "Give Me" arrive, but the song also finally hits iTunes. Her movie "W.E." also opens that day.

"Give Me All Your Luvin' " is the lead single off her new album M.D.N.A., which drops March 26.

Related Artists

• Madonna

Source: http://www.mtv.com/news/articles/1678109/madonna-music-video-cheerleader.jhtml

steve o greg giraldo greg giraldo bob hope mariano rivera mariano rivera dadt repeal

Iran official says oil will reach $150 per barrel (AP)

TEHRAN, Iran ? Iran's official news agency reports that the head of the state oil company is claiming that the price of crude will go up to $150 per barrel.

Head of the National Iranian Oil Company Ahmad Qalehban did not give a time frame for the prediction, nor any other details in the Sunday report by IRNA.

The price of benchmark U.S. crude on Friday was around $99.56 per barrel.

Qalehban's statement comes as Iranian officials prepare to debate a ban on crude sales to European Union countries, in response to a planned EU embargo on Iran's oil by summer because of that country's nuclear program.

The United States and its allies argue that Iran is trying to develop nuclear weapons technology, while Tehran says the program is for purely peaceful purposes.

Source: http://us.rd.yahoo.com/dailynews/rss/iran/*http%3A//news.yahoo.com/s/ap/20120129/ap_on_re_mi_ea/ml_iran_oil

mumia mumia uss arizona memorial uss arizona memorial d day fun. words with friends

Gingrich???s Space Colony Proposition Unrealistic (ContributorNetwork)

COMMENTARY | Apparently the moon is the next prime real estate for U.S. citizens, or so former Speaker of the House and Republican presidential candidate Newt Gingrich seems to think.

In the Thursday Florida primary debate, Gingrich expanded on his previous claim that if elected president, he would make every effort to establish a space colony on the moon by 2020. What's more, it's estimated 13,000 inhabitants would be able to qualify for American citizenship.

This illustrious plan sounds a bit "spacey" to me. Just think: A presidential nominee who supposedly recognizes the economic woes that Americans have been facing and who bashes President Barack Obama for misallocation of national funds and ill-conceived solutions to bring the country back from its multitrillion-dollar deficit has the notion that American taxpayers have the means to support a colony in space.

I understand the argument that commercializing NASA and other space exploits is a compromising method to not let expensive equipment go to waste. I get that for Americans to remain a dominant world power, they must retain a presence in space.

But the convoluted part for me is how repurposing space equipment on Earth is going to ready average U.S. citizens for eventual long-term establishment in space. That begs the question of how Gingrich expects to pay for it, with so many other philanthropies vying for funding. I also wonder how Gingrich plans for Americans to remain the lone nationality represented on the moon.

The 1961 lunar landing guaranteed the U.S. a place in space race history. Chances are NASA wouldn't have made nearly the number of discoveries and strides in its 30 years if the U.S. hadn't laid the foundation early. But is a space colony the type of semi-permanent mark Americans want to make without funds to accommodate it?

It may do Gingrich well to recall another memorable point in the history of U.S. colonization, when the British colonies were established in North America but were expected to pay the same taxes as those residing in England.

Gingrich might soon realize his flat tax initiative is a bust with the anticipated tax inflation and strain a space colony would put on Americans in the U.S. The sheer amount of resources needed to sustain a colony on the moon would be astronomical. Not only would U.S. space residents lose their national identity and affiliation; I'm sure that terra firma-lovers would realize the wasted allocation of money resources to sustain their brothers in orbit. Sounds eerily similar to Gingrich's own sentiments about the current commander-in-chief.

An American-only space colony is an impressive campaign goal, but it may be a bit too lofty for Gingrich or others to achieve in the current economic climate. There's no doubt that it's a project that could take off in the distant future; after all, the U.S. did put a man on the moon. It has no chance, though, until financial feasibility catches up to American capability.

Source: http://us.rd.yahoo.com/dailynews/rss/space/*http%3A//news.yahoo.com/s/ac/20120129/pl_ac/10893623_gingrichs_space_colony_proposition_unrealistic

breedlove knicks oklahoma city thunder florida state football florida state football ben breedlove kid cudi ben breedlove

Report: Nintendo Considering Changing The Wii U?s Name

The Wii U brand is a bit underwhelming. At best it builds upon a very successive product. But at worst the name suggests its simply an add-on rather than a completely revamped system. A new report just surfaced that sources a Nintendo insider stating the company is considering renaming the next-gen Wii. Nintendo is quickly spiraling down. The Wii U -- or whatever it's to be called -- needs to be a hit. Nintendo cannot misplace another piece in Tetris.

Source: http://feedproxy.google.com/~r/Techcrunch/~3/Dc-2ae9KAu4/

donald glover julio cesar chavez jr jason segel turducken power rangers jungle fury power rangers jungle fury ufc 139 fight card